Cambio - Excellence in Molecular Biology

PCR

PCR : Rest DNA Testing

Detection of residual host cell DNA by dPCR with MiQuant® Residual DNA dPCR kits for E. coli, CHO or HEK-293:

  • Novel rapid, robust and sensitive method
  • Samples can be tested without performing DNA extraction
  • Meets EP, WHO and FDA criteria
  • Designed for use with the QIAGEN® QIAcuity® dPCR system
  • Aliquoted PCR mix ensures long-term stability
  • Lyophilized kit components simplify logistics and storage

 

Background & Description

Chinese hamster ovary cells (CHO), E. coli, and human embryonic kidney cells (HEK-293) have been widely used to manufacture recombinant proteins for human therapeutic use. After the synthesis of such immunotherapeutic or biosimilar, it is found that there could be some residual presence of DNA from the host cell. The World Health Organization (WHO), the Food and Drug Agency (FDA), and the European Pharmacopoeia (EP) recommend that the residual DNA in a manufactured final product needs to be less than 10 ng/dose. Even though downstream purification processes remove host cell residual DNA traces from products, testing for residual DNA is significant to ensure the customers’ safety.

The use of digital PCR (dPCR) is a very efficient way to determine the concentration of residual DNA in the final product. The MiQuant® Residual DNA dPCR kits for CHO, E. coli, and HEK-293 are the most accurate, efficient, and cost-effective way to analyze residual DNA in a sample without DNA extraction.

The kits are designed for QIAGEN®s QIAcuity® dPCR system as a novel rapid, robust, and sensitive method for absolute DNA quantification. This technology reduces the time needed for testing to less than three hours, including the dPCR sample preparation and thermocycling. Also, using these kits increases sensitivity since no DNA is lost during the extraction.

Short multicopy targets in the CHO (repeated element, ~ 1 million copies per genome), E. coli (7 genome copies), and HEK-293 (repeated element, ~ 1 million copies per genome) genomes are amplified. The length of the amplicons is < 200 bp and, therefore, short enough to allow the amplification of highly degraded DNA according to guidelines.

Moreover, each kit contains all the necessary PCR components, including Taq polymerase, primers, and dNTPs in a lyophilized mix, the Rehydration Buffer, dPCR Grade Water, and lyophilized Internal Control. The Internal Control is very reliable and will indicate any false negative result caused by PCR inhibition.

 

MiQuant® AAV kits - coming soon

Determination of adeno-associated virus vector titer by digital PCR with MiQuant® AAV.

Minerva Biolabs

Description

  • Fast and easy workflow
  • Quantitation independent of AAV serotype
  • No DNA extraction required
  • Designed for QIAcuity platform
  • In-Process Control and Release Testing
  • Quantitation without standard curve or further calculations
  • Lyophilised kit components simplify logistics and storage

Gene therapy represents one of the most ground-breaking advancements in modern medicine that has rapidly evolved over the last years leading to improved methods of applications. Adeno-associated virus (AAV) vectors are among the most prominent viral vectors for in vivo gene therapy that target the healthy gene material to the correct location in the organism which enables the mutated gene to be exchanged by the healthy one.


Viral genome titre is a critical quality attribute in AAV characterization for safe and efficacious gene therapy products. Specificity of AAV vectors as well as the concentration of the vector titre must be determined throughout the production process and for final release testing.


The MiQuant® AAV kits have been developed for the determination of AAV vector titre. Different kit versions enable the specific detection of AAV genotype 2/6 (including genotype 1, 3 & 7) or genotype 5

.

 

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200

Applications & Benefits

Determination of the AAV vector titer with the MiQuant® AAV kits is useful at different times. During the AAV vector production process, it can be used as an in-process control to evaluate the AAV titer. As part of the final QC release testing the AAV titer must be determined prior to administration to the patient. Besides these applications the MiQuant® AAV kits can also be used for determining the AAV titer in research and development.

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200